Stock Watch: The Complex Biologics Market Is…Complex
Lovenox And Copaxone Generic Challenges Foreshadow Biosimilar Market Inhibition
Executive Summary
The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.
You may also be interested in...
Stock Watch: The Meaning Of Biosimilar Success
With two recent divestments of biosimilar franchises and lackluster performances from smaller biosimilar biotechs, the sector needs some standard-bearing successes.
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?